This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
ECLIPSE Trial
Oral EPI-7386
SPLASH Trial
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO 2023
AUA 2023
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
ASCO 2023: PROPELLER: 64Cu-SAR-bisPSMA PET Imaging in Patients with Confirmed Prostate Cancer
June 5, 2023
ASCO 2023: Concurrent Chemo-Hormonal Therapy of Enzalutamide and Cabazitaxel in Patients with mCRPC: Final Analysis of ORR, rPFS, and OS
June 5, 2023
ASCO 2023: Independent Biomarkers Predictive of Outcomes with Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study
June 5, 2023
ASCO 2023: Biomarkers of Response to Sacituzumab Govitecan and Efficacy After Treatment with Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of the UNITE Study
June 5, 2023
ASCO 2023: Final Results from SAUL, a Single-Arm International Real-World Study of Atezolizumab in Patients with Pretreated Locally Advanced/Metastatic UTC
June 5, 2023
ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data
June 5, 2023
ASCO 2023: Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell Carcinoma: An Analysis from the SWOG S1500 (PAPMET) Trial
June 5, 2023
ASCO 2023: Discussant: Germinating Data for Germ Cell Tumors
June 5, 2023
ASCO 2023: Discussant: DDR and PARP Inhibition: What's the Damage?
June 5, 2023
ASCO 2023: PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 + Standard of Care and Standard of Care Alone in Patients with mHSPC
June 5, 2023
ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations
June 5, 2023
ASCO 2023: Presence of Somatic/Germline Homologous Recombination Repair Mutations and Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving First‑line Treatment Stratified by BRCA Status
June 5, 2023
ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
June 5, 2023
ASCO 2023: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
June 5, 2023
ASCO 2023: Discussant: Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety
June 4, 2023
ASCO 2023: Primary RPLND in Seminoma Stage IIA-IIC ≤3cm: Combined Results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne
June 4, 2023
ASCO 2023: Molecular Drivers of Organotropism and Cisplatin Resistance in Germ Cell Tumors
June 4, 2023
ASCO 2023: Discussant: Hitting the Sweet Spot with Radiation and Androgen Deprivation
June 4, 2023
ASCO 2023: Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated in the US: The Non-Interventional REASSURE Study
June 4, 2023
ASCO 2023: Discussant: The Power of Patients' Experiences to Inform Therapeutic Decisions
June 4, 2023
Page 2 of 522
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free